Chinese General Practice ›› 2022, Vol. 25 ›› Issue (29): 3640-3645.DOI: 10.12114/j.issn.1007-9572.2022.0320
• Article • Previous Articles Next Articles
Received:
2022-04-22
Revised:
2022-06-02
Published:
2022-10-15
Online:
2022-07-14
Contact:
Songze DING
About author:
通讯作者:
丁松泽
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0320
药品名称 | 药品规格 | 药品价格 | 生产厂商 |
---|---|---|---|
雷贝拉唑钠肠溶片 | 10 mg×18片 | 35.98元/盒 | 江苏豪森药业集团有限公司 |
阿莫西林分散片 | 0.25 g×24片 | 23.76元/盒 | 山西同达药业有限公司 |
呋喃唑酮片 | 0.1 g×100片 | 12.65元/瓶 | 山西云鹏制药有限公司 |
枸橼酸铋钾颗粒 | 110 mg×40粒 | 9.73元/盒 | 山西云鹏制药有限公司 |
Table 1 Specifications and retail prices of four drugs
药品名称 | 药品规格 | 药品价格 | 生产厂商 |
---|---|---|---|
雷贝拉唑钠肠溶片 | 10 mg×18片 | 35.98元/盒 | 江苏豪森药业集团有限公司 |
阿莫西林分散片 | 0.25 g×24片 | 23.76元/盒 | 山西同达药业有限公司 |
呋喃唑酮片 | 0.1 g×100片 | 12.65元/瓶 | 山西云鹏制药有限公司 |
枸橼酸铋钾颗粒 | 110 mg×40粒 | 9.73元/盒 | 山西云鹏制药有限公司 |
组别 | 例数 | 性别〔n(%)〕 | 年龄( | BMI ( | BSA ( | 吸烟〔n(%)〕 | 饮酒〔n(%)〕 | ||
---|---|---|---|---|---|---|---|---|---|
男 | 女 | ||||||||
A组 | 55 | 28(50.9) | 27(49.1) | 44.2±10.9 | 23.7±3.1 | 1.81±0.16 | 10(18.2) | 14(25.5) | |
B组 | 54 | 26(48.1) | 28(51.9) | 41.1±12.4 | 23.1±3.0 | 1.83±0.19 | 9(16.7) | 13(24.1) | |
C组 | 52 | 25(48.1) | 27(51.9) | 40.0±11.2 | 22.9±3.0 | 1.80±0.18 | 8(15.4) | 6(11.5) | |
χ2(F)值 | 0.113 | 2.010a | 0.897a | 0.421a | 0.150 | 3.815 | |||
P值 | 0.945 | 0.137 | 0.421 | 0.657 | 0.928 | 0.148 | |||
组别 | 文化程度〔n(%)〕 | 家庭成员感染情况〔n(%)〕 | 外出就餐情况〔n(%)〕 | ||||||
小学及以下 | 初中 | 高中 | 大学及以上 | 是 | 否 | 不清楚 | <3次/周 | ≥3次/周 | |
A组 | 5(9.1) | 7(12.7) | 12(21.8) | 31(56.4) | 25(45.5) | 20(36.4) | 10(18.2) | 36(65.5) | 19(34.5) |
B组 | 3(5.6) | 5(9.3) | 9(16.7) | 37(68.5) | 21(38.9) | 25(46.3) | 8(14.8) | 28(51.9) | 26(48.1) |
C组 | 4(7.7) | 10(19.2) | 5(9.6) | 33(63.5) | 19(36.5) | 19(36.5) | 14(26.9) | 31(59.6) | 21(40.4) |
χ2(F)值 | 5.550 | 3.521 | 2.096 | ||||||
P值 | 0.479 | 0.475 | 0.351 |
Table 2 Comparison of general data among three groups
组别 | 例数 | 性别〔n(%)〕 | 年龄( | BMI ( | BSA ( | 吸烟〔n(%)〕 | 饮酒〔n(%)〕 | ||
---|---|---|---|---|---|---|---|---|---|
男 | 女 | ||||||||
A组 | 55 | 28(50.9) | 27(49.1) | 44.2±10.9 | 23.7±3.1 | 1.81±0.16 | 10(18.2) | 14(25.5) | |
B组 | 54 | 26(48.1) | 28(51.9) | 41.1±12.4 | 23.1±3.0 | 1.83±0.19 | 9(16.7) | 13(24.1) | |
C组 | 52 | 25(48.1) | 27(51.9) | 40.0±11.2 | 22.9±3.0 | 1.80±0.18 | 8(15.4) | 6(11.5) | |
χ2(F)值 | 0.113 | 2.010a | 0.897a | 0.421a | 0.150 | 3.815 | |||
P值 | 0.945 | 0.137 | 0.421 | 0.657 | 0.928 | 0.148 | |||
组别 | 文化程度〔n(%)〕 | 家庭成员感染情况〔n(%)〕 | 外出就餐情况〔n(%)〕 | ||||||
小学及以下 | 初中 | 高中 | 大学及以上 | 是 | 否 | 不清楚 | <3次/周 | ≥3次/周 | |
A组 | 5(9.1) | 7(12.7) | 12(21.8) | 31(56.4) | 25(45.5) | 20(36.4) | 10(18.2) | 36(65.5) | 19(34.5) |
B组 | 3(5.6) | 5(9.3) | 9(16.7) | 37(68.5) | 21(38.9) | 25(46.3) | 8(14.8) | 28(51.9) | 26(48.1) |
C组 | 4(7.7) | 10(19.2) | 5(9.6) | 33(63.5) | 19(36.5) | 19(36.5) | 14(26.9) | 31(59.6) | 21(40.4) |
χ2(F)值 | 5.550 | 3.521 | 2.096 | ||||||
P值 | 0.479 | 0.475 | 0.351 |
组别 | 例数 | 恶心 | 呕吐 | 腹痛 | 腹泻 | 皮疹 | 头晕 | 心悸 | 乏力 | 厌食 | 其他 | 合计 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
A组 | 52 | 10(19.2) | 1(1.9) | 1(1.9) | 1(1.9) | 0 | 2(3.8) | 0 | 2(3.8) | 1(1.9) | 2(3.8) | 20(38.5) |
B组 | 53 | 2(3.8) | 0 | 0 | 0 | 0 | 1(1.9) | 0 | 0 | 1(1.9) | 0 | 4(7.5)a |
C组 | 49 | 3(6.1) | 0 | 2(4.1) | 1(2.0) | 0 | 1(2.0) | 1(2.0) | 2(4.1) | 1(2.0) | 2(4.1) | 13(26.5)b |
χ2值 | 8.203 | 1.806 | 2.021 | 1.324 | — | 0.659 | 1.925 | 2.243 | 0.003 | 2.243 | 13.989 | |
P值 | 0.017 | 0.656 | 0.210 | 0.546 | — | 0.844 | 0.318 | 0.395 | 0.998 | 0.395 | 0.001 |
Table 3 Treatment-related adverse reactions in three groups
组别 | 例数 | 恶心 | 呕吐 | 腹痛 | 腹泻 | 皮疹 | 头晕 | 心悸 | 乏力 | 厌食 | 其他 | 合计 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
A组 | 52 | 10(19.2) | 1(1.9) | 1(1.9) | 1(1.9) | 0 | 2(3.8) | 0 | 2(3.8) | 1(1.9) | 2(3.8) | 20(38.5) |
B组 | 53 | 2(3.8) | 0 | 0 | 0 | 0 | 1(1.9) | 0 | 0 | 1(1.9) | 0 | 4(7.5)a |
C组 | 49 | 3(6.1) | 0 | 2(4.1) | 1(2.0) | 0 | 1(2.0) | 1(2.0) | 2(4.1) | 1(2.0) | 2(4.1) | 13(26.5)b |
χ2值 | 8.203 | 1.806 | 2.021 | 1.324 | — | 0.659 | 1.925 | 2.243 | 0.003 | 2.243 | 13.989 | |
P值 | 0.017 | 0.656 | 0.210 | 0.546 | — | 0.844 | 0.318 | 0.395 | 0.998 | 0.395 | 0.001 |
[1] |
国家消化系疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组,等. 中国居民家庭幽门螺杆菌感染的防控和管理专家共识(2021年)[J]. 中华消化杂志,2021,41(4):221-233. DOI:10.3760/cma.j.cn311367-20210219-00108.
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
袁培杰,李夏平,李乐谦,等. 高剂量二联疗法与经典四联疗法根除幽门螺杆菌的疗效对比[J]. 现代消化及介入诊疗,2021,26(6):681-684. DOI:10.3969/j.issn.1672-2159.2021.06.004.
|
[10] | |
[11] |
齐尔旋,周丽雅. 阿莫西林和克拉霉素最小抑菌浓度折点对含其幽门螺杆菌根除方案疗效的影响[J]. 中华消化杂志,2021,41(6):385-391. DOI:10.3760/cma.j.cn311367-20201030-00638.
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
李晓娟,李哲轩,汤富兵,等. 幽门螺杆菌根除效果影响因素分析[J]. 中华肿瘤防治杂志,2015,22(15):1165-1169. DOI:10.16073/j.cnki.cjcpt.2015.15.001.
|
[1] | DU Junyan, PAN Jie, ZHOU Qingjie, TANG Qingqing, YANG Ningmin, ZHANG Jianzhong. The Helicobacter Pylori Antibiotic Resistance in Wenzhou, Zhejiang from 2013 to 2020 [J]. Chinese General Practice, 2023, 26(07): 825-829. |
[2] | Miao YU, Xiaoxia SONG, Jing MA, Qiaoqiao SHAO, Xuechun YU, Yabin QI, Ruobing HU, Peiru WEI, Wei XIAO, Bailing JIA, Yanbo CHENG, Lingfei KONG, Chuanliang CHEN, Songze DING. Relationship between Helicobacter pylori Infection and Precancerous Lesions of Gastric Mucosa in Children in Central Plain Area of China [J]. Chinese General Practice, 2022, 25(23): 2849-2855. |
[3] | GUAN Yazhe,WU Siqi,ZHANG Xue,HE Yutong. Recent Advances in Research on Cost-effectiveness of Colorectal Cancer Screening [J]. Chinese General Practice, 2021, 24(33): 4177-4184. |
[4] | LIN Qiuman,WANG Guiliang,QIU Ping,XU Linfang,GONG Min,HAN Ming,LI Xing,WEN Jianbo. Hypertonic Glucose Versus Lauromacrogol with Cyanoacrylate Sandwich Therapy for Gastroesophageal Variceal Hemorrhage:a Cost-effectiveness Analysis [J]. Chinese General Practice, 2020, 23(8): 974-979. |
[5] | WU Zhonglin,WU Yongchao,RONG Xiaocui,GU Tieshu,HAO Xiaoguang,YANG Dongqiang,LI Shunzong. Screening of Optimal Liver Protection Scheme for Acute Liver Injury Induced by Transarterial Chemoembolization in Primary Liver Cancer [J]. Chinese General Practice, 2019, 22(26): 3159-3164. |
[6] | WANG Xi,YUAN Shuting,BAI Qian,WU Jiang,SHI Xuefeng. Cost-benefit Analysis of Emergency Hepatitis B Vaccination in Beijing from 1992 to 2013 [J]. Chinese General Practice, 2019, 22(25): 3116-3120. |
[7] | XU Kangjie,JIANG Hua,LIU Nana,XIAO Yue,GONG Xin,BO Xiaojie,WANG Chunxu,CHEN Ning,GENG Shasha,WANG Chaoxin. Economic Benefit Analysis of Risk-based Screening of Pancreatic Cancer [J]. Chinese General Practice, 2018, 21(28): 3513-3517. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||